Regeneron expects Q4 IPR&D charge of ~$19M and $60M matching donation charge

REGENERON PHARMACEUTICALS, INC.

Expects ~$19M pre-tax IPR&D charge in Q4 2025, reducing GAAP and non-GAAP diluted EPS by ~$0.14.
Records ~$60M SG&A charge for matching donations to Good Days retinal fund in Q4 2025.
Preliminary Q4 and FY2025 financial update provided at J.P. Morgan Healthcare Conference.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.